Enterprise League logo
Cerebral Innovations Logo

Cerebral Innovations

Saint Petersburg, United States (US) · Health and Medical

We built this page from public sources. What we do with your data

Do you work at Cerebral Innovations?

Claim this profile to manage your company.

Verified by Enterprise League

Data quality

Complete · Accuracy

#fda

#clinical outcome assessments

#coa

#digitized spiral drawing

#type c feedback

#21 cfr part 11

#patient focused drug development

#ai

#parkinson's disease

#essential tremor

Cerebral Innovations is a US-based biotechnology research company specializing in digitized spiral drawing assessment for clinical trials, headquartered in Saint Petersburg, Florida.We employ modern computerized endpoints into clinical trials to increase treatment effect sensitivity, thus improving your odds of a successful clinical trial.What sets Cerebral Innovations apart is our commitment to regulatory-grade, objective digital endpoints, compliant with 21 CFR Part 11, EU GMP Annex 11, and GxP standards.

Overview

Cerebral Innovations is a US-based biotechnology research company specializing in digitized spiral drawing assessment for clinical trials, headquartered in Saint Petersburg, Florida.

We employ modern computerized endpoints into clinical trials to increase treatment effect sensitivity, thus improving your odds of a successful clinical trial.

What sets Cerebral Innovations apart is our commitment to regulatory-grade, objective digital endpoints, compliant with 21 CFR Part 11, EU GMP Annex 11, and GxP standards. Our platform, NeuroQuantix, standardizes 35+ years of published spiral analysis research into a single endpoint platform, offering pre-specified, defensible endpoints for Phase 2/3 efficacy trials and enabling powered studies with fewer subjects.

NeuroQuantix provides the objective, quantitative motor endpoints across 23 neurological conditions that clinical trials demand and regulators increasingly expect, offering solutions for Phase 1-2 de-risking, gene therapy, rare disease studies, drug safety monitoring, and natural history studies.
Visit Official Website

Most teams do this before shortlisting


Contact Details

david@cerebral-innovations.com

Saint Petersburg, United States (US)

Company Type

Private Limited Company

Employees

2-10

Categories

Biopharma
Life Science
Biotechnology

Keywords

#fda

#clinical outcome assessments

#coa

#digitized spiral drawing

#type c feedback

#21 cfr part 11

#patient focused drug development

#ai

#parkinson's disease

#essential tremor

Awards

• 2026 OpenSee all

Products

Default Product Image
NeuroQuantix Platform
Biotechnology

NeuroQuantix is a digitized spiral drawing assessment platform designed for clinical trial regulatory submission. It provides objective, quantitative motor endpoints across 23 neurological conditions, compliant with 21 CFR Part 11, EU GMP Annex 11, and GxP standards. The platform utilizes a deep kinematic library and iPad-based assessment for minimal site burden.

N/A


Services

Default Product Image
Clinical Trial Endpoints Consulting
Biotechnology

Cerebral Innovations offers consulting services to help clients select and implement pre-specified, defensible endpoints for clinical trials. Our expertise in digitized spiral analysis and regulatory compliance ensures a robust endpoint strategy.

N/A

Companies teams usually look at after Cerebral Innovations

Comparing a few options usually leads to better decisions






  • Save companies to compare later. Useful when sharing options with your team

This is how your company profile looks to others.